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a b s t r a c t
The immune response of hemophilia A patients to administered FVIII is a major complication that obvi-
ates this very therapy. We have recently described the use of synthetic, biodegradable nanoparticles car-
rying rapamycin and FVIII peptide antigens, to induce antigen-specific tolerance. Herein we test the
tolerogenicity of nanoparticles that contains full length FVIII protein in hemophilia A mice, focusing on
anti-FVIII humoral immune response. As expected, recipients of tolerogenic nanoparticles remained
unresponsive to FVIII despite multiple challenges for up to 6 months. Furthermore, therapeutic treat-
ments in FVIII-immunized mice with pre-existing anti-FVIII antibodies resulted in diminished antibody
titers, albeit efficacy required longer therapy with the tolerogenic nanoparticles. Interestingly, durable
FVIII-specific tolerance was also achieved in animals co-administered with FVIII admixed with nanopar-
ticles encapsulating rapamycin alone. These results suggest that nanoparticles carrying rapamycin and
FVIII can be employed to induce specific tolerance to prevent and even reverse inhibitor formation.
Published by Elsevier Inc.
1. Introduction
Replacement therapy for monogenic diseases, such as hemophi-
lia A and B [1,2] and Pompe Disease [3], is complicated by the
adverse immune response against the therapeutic protein [4]. For
example, 25–30% of hemophilia A patients develop anti-FVIII
inhibitory antibodies (inhibitors), which render the life-saving
therapy itself ineffective [5]. The major approach to reverse
inhibitor formation is ‘‘immune tolerance induction (ITI)” therapy,
a protocol that requires regular high dose FVIII infusion for months
to years. ITI is costly and fails in a significant number of patients,
especially those with high titer inhibitors [6]. Hence, novel and
durable antigen-specific tolerogenic therapy would be highly
desirable from an efficacy and safety perspective.
Multiple techniques for antigen-specific immunotherapy for
undesirable immune responses have been described, primarily in
pre-clinical models, but translation to human clinical trials has
been limited [7]. Strategies to induce tolerance include conjugating
antigen to splenocytes [8], immature dendritic cells (DC) [9,10], or
synthetic microparticles [11,12], oral tolerance [13], gene therapy
[14] or co-treatment with immunosuppressive drugs, such as
methotrexate [15]. Recently, it has been reported that systemic
co-administration of rapamycin, a immunosuppressant drug com-
monly used to prevent transplant rejection, prevented immune
response and induced tolerance to FIX and FVIII in mouse models
of hemophilia A and B, respectively [29,30].
Our goal was to develop a simple and effective protocol to
induce tolerance to FVIII, both prophylactically and therapeuti-
cally. Based on the advantage of using a therapeutic nanoparticle
delivery system [16–19], as well as the evidence that rapamycin
treatment promotes tolerance induction both in vitro and in vivo
[10,21,29,30], we developed tolerogenic synthetic vaccine particles
(SVP) by incorporating rapamycin in self-assembling, biodegrad-
able nanoparticles comprised of poly(lactic-co-glycolic acid)
(PLGA), a polymer found in multiple medical products [20].
The use of these tolerogenic nanoparticles incorporating rapamy-
cin could eliminate the need for chronic use of immunosuppressive
systemic drugs.
Herein, we show that co-administration of SVP with FVIII led to
specific unresponsiveness that was long-lasting and effective in
FVIII knockout mice in a prophylactic protocol even with multiple
challenges with immunogenic doses of FVIII. Moreover, an ongoing
immune response in FVIII-primed mice could also be reversed by
these SVPs, resulting in correction of bleeding phenotype following
FVIII infusion.
http://dx.doi.org/10.1016/j.cellimm.2015.11.004
0008-8749/Published by Elsevier Inc.
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2. Materials and methods
2.1. Reagents
NPs were prepared as described and provided courtesy of Dr.
Kei Kishimoto, Selecta Biosciences [20]. Briefly, for preparing SVP
containing rapamycin and FVIII protein (Fig. 1A), PLGA, PLA-PEG,
and rapamycin were dissolved in dichloromethane to form an oil
phase. An aqueous solution of recombinant human FVIII (Advate,
Baxalta) was then added to the oil phase and emulsified by sonica-
tion. Following emulsification of the antigen solution into the oil
phase, a double emulsion was created by adding an aqueous solu-
tion of polyvinyl alcohol and sonicating a second time. The double
emulsion was added to a beaker containing phosphate buffer solu-
tion and stirred at room temperature for 2 h to allow the dichlor-
omethane to evaporate. When creating SVP contains rapamycin
but no antigen (Fig. 3A), or NPs without any encapsulated agents,
a similar oil-in-water single emulsion process was used. The
resulting NPs were washed by centrifuging at 75,600g and 4 C
followed by re-suspension of the pellet in PBS. Tolerogenic NP
injections typically consisted of 30–100 lg of rapamycin content.
Recombinant human FVIII (Baxalta) was used for immunization
intravenously or intraperitoneally at 1 lg per injection; uX174 was
provided by Dr. Hans Ochs (Seattle Children’s Hospital). Sheep red
blood cells (SRBC) were purchased from Innovative Research, Inc.,
(Novi, MI), and 2,4,6-Trinitrophenyl conjugated SRBC was prepared
as described [23].
2.2. Animals
FVIII/ mice (E16) on C57BL/6 background were originally
obtained from Dr. Leon Hoyer at the American Red Cross [24]. All
animals were housed and bred at the animal facilities operated
by the Uniformed Services University of the Health Sciences
(USUHS) Laboratory Animal Medicine facility, and animal protocols
were approved by the Institutional Animal Care and Use Commit-
tee of USUHS.
2.3. Bleeding assay
Phenotypic correction of hemophilia A mice in response to ther-
apeutic FVIII was assessed using a tail bleeding assay with modifi-
cation [22]. Hemophilia A mice were injected with 1 lg FVIII in
100 ll PBS through the retro-orbital sinus. Five minutes after the
injection, the tail tip was transected using a 1.6 mm diameter tem-
plate without subsequent cauterization. Fifty microliter hep-
arinized blood was collected through retro-orbital bleeding
before the FVIII injection (0 h time point) and 6 h after the tail
tip transection (6 h time point). Hemoglobin (Hb) levels in the
blood were measured using Drabkin’s reagent. Briefly, 4 ll of
whole blood was mixed into 1 ml of Drabkin’s solution at room
temperature, and the absorbance at 540 nm was measured
15 min later. A standard curve was generated using bovine hemo-
globin standards. The Hb levels at 6 h time point were normalized
to the value at 0 h, and the result was reported as% normalized
hemoglobin. The same protocol was also performed on a group
of wild type C57Bl/6 mice (WT), except without FVIII injection.
2.4. Immunologic assays
FVIII activity was assayed using the chromogenic functional
assay (Coatest SP4 FVIII, DiaPharma). ELISA and Bethesda assays
for measuring anti-FVIII IgG titer and for the FVIII inhibitor titer,
respectively, were performed as previously described [14,25].
Anti-trinitrophenyl and anti-uX174 titers were performed by
ELISA on haptenated-BSA and uX174-coated plates, respectively.
Anti-SRBC titer was determined by hemagglutination (HA) assay
as described [26].
2.5. Statistics
Normal distribution data were compared using a 2-tailed
unpaired Student’s t test. If the data did not meet the Shapiro–Wilk
test for normality, the Mann–Whitney U test was performed. Data
are presented as mean ± SEM, or otherwise as indicated. A p value
of less than 0.05 was considered significant.
3. Results
3.1. Prophylactic treatment in hemophilia A mice
To test the efficacy of SVP containing FVIII protein and rapamy-
cin, we first treated naïve E16 mice. These mice have a targeted dis-
ruption of FVIII exon 16 which results in an undetectable level of
FVIII activity; such E16 mice have been used as a small animal
model for severe hemophilia A [27]. E16 mice (n = 8–10 animals/-
group) were treated weekly for 5 weeks with test SVP or control
empty NP through i.v. route (Fig. 1B). For the last three doses, the
mice were co-administered with an immunogenic dose of FVIII.
As expected, mice treated with empty nanoparticle (empty NP)
control showed a robust anti-FVIII antibody response with a mean
level of 18.4 lg/ml (4.2–45.8 lg/ml), one week after the 3rd FVIII
exposure. In contrast, the anti-FVIII titer was undetectable in mice
treated with 5 doses of SVP. To confirm the unresponsiveness to
FVIII, the mice were challenged again with FVIII on day 21. Three
weeks later at day 42, 7 out 8mice in the SVP group remained unde-
tectable for anti-FVIII titer, while the anti-FVIII level in the control
group continued increase to a mean level of 34.6 lg/ml (Fig. 1C).
3.2. Tolerance to FVIII induced was long-lasting
The mice were rested for additional 3 weeks and then chal-
lenged with 3 more weekly injections of immunogenic doses of
FVIII. As shown in Fig. 1C, the control group mice (black dots) fur-
ther responded with peak mean levels of anti-FVIII at 49.1 lg/ml.
Following the same treatments, the peak mean anti-FVIII levels
were 14.8 lg/ml in SVP group. Removal of one outlier resulted in
a peak mean anti-FVIII levels of only 1.9 ± 0.6 lg/ml (0–3.2 lg/
ml), which was 25-fold less than that of control group. The anti-
FVIII inhibitor titer showed a similar trend (Fig. 1D). On day 65, a
bleeding assay was performed. A group of wild type (WT)
C57BL/6 mice were included in order to establish base line. As
shown in Fig. 1G, the blood loss in WT mice resulted in normalized
Hemoglobin (Hb) of 78.1 ± 5.3%. FVIII injection in the empty NP
group mice failed to rescue the hemophilia phenotype of E16 mice,
due to the presence of high titer anti-FVIII inhibitors. The normal-
ized Hb levels were 63.3 ± 2.1% in the empty NP group, signifi-
cantly lower than that of WT group. In the contrast,
administration of FVIII in SVP-treated animals 5 min before the
bleeding assay procedure completely rescued the hemophilia
phenotype, resulting in 85.9 ± 5.9% normalized Hb levels.
3.3. Normal antibody response to TNP antigen
Tolerance to FVIII developed in the SVP group was antigen-
specific, as these mice responded normally to immunization with
a non-related antigen, TNP (Fig. 1F). The mice received three
weekly i.v. injections of TNP-SRBC between day 42 and 58. As early
as one week after the 1st TNP-SRBC dose, the majority of the mice
in both groups responded with anti-TNP antibodies, which further
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increased with additional injections. There was no significant dif-
ference between the two groups at any time point.
3.4. Therapeutic treatment of an emerging anti-FVIII immune response
We next assessed the ability of SVP to therapeutically inhibit an
emerging immune response in E16 mice primed with FVIII
(Fig. 2A). Mice received 4 injections of low dose FVIII (0.1 lg) on
days 0, 7, 14, and 25 followed by two doses of high dose FVIII
(1 lg) on days 34 and 42. FVIII inhibitor titers were assessed on
days 25, 34, 42, and 51. Animals that had low but detectable levels
of inhibitors on Day 51 were randomized to either empty NP or SVP
treatment (Fig. 2B). Animals received two courses of 5 weekly
injections of nanoparticles concurrently with FVIII (1 lg) starting
Fig. 1. Prophylactic efficacy of SVP in E16 mice. (A) Illustration of SVP encapsulating with both rapamycin and full length FVIII protein. (B) Dose regimen. E16 mice were
treated with either SVP or control empty NP through i.v. on days 14, 7 and 0. Both groups received recombinant human FVIII (1 lg) on days 0, 7, 14, 21, 42, 50, and 58 and
were also immunized with trinitrophenol-conjugated sheep red blood cells (TNP-SRBC) on days 42, 50 and 58. (C) Anti-FVIII antibodies were determined by ELISA. (D) Anti-
FVIII antibodies in animals treated with 5 doses of empty SVP (black) vs SVP (blue) after removal of a single outlier from the SVP group. (E) FVIII inhibitor titers were
determined by measuring Bethesda Units. (F) Anti-TNP-SRBC antibodies were determined by ELISA. (G) The correction of bleeding phenotype in the E16 mice as revealed by%
normalized hemoglobin (Hb) in a bleeding assay. #p < 0.05 compared to empty NP group by Mann Whitney U test with two tailed distribution; *p < 0.05 and **p < 0.01
compared to empty NP group by Student t test with two tailed distribution. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
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on days 68 and 125 (Fig. 2A). Animals treated with empty
nanoparticle control showed a variable but significant anti-FVIII
antibody response (Fig. 2C and D, black symbols). Mice treated
with SVP initially showed a variable response to FVIII, with some
animals exhibiting high levels of anti-FVIII antibodies while other
animals remained low (Fig. 2C, blue symbols). Importantly, after
the start of the second course of treatment on Day 125, animals
treated with SVP showed a substantial reduction in antibody levels
(Fig. 2C and D, blue symbols). Analysis of FVIII inhibitors showed a
similar trend (Fig. 2E), although there was more variability in the
levels of inhibitors between time points in the SVP group. A bleed-
ing assay was performed in some of the mice on day 216, about
2 months after the final concurrent dose of nanoparticles and FVIII.
Compared to the WT group (78.1 ± 5.3%, see Fig. 1G), the%
normalized Hb levels in empty NP and SVP groups were
65.5 ± 4.4% and 95.6 ± 3.0%, respectively (Fig. 2F).
3.5. Tolerance induction using SVP that contains rapamycin only
Experiments were performed in E16 mice to determine the effi-
cacy of SVP that contains rapamycin only (Fig. 3A), since we
observed that FVIII protein was able to physically bind to the SVP
after mixing together (Fig. 3B). To ensure NP mediated co-
delivery of FVIII antigen and rapamycin to the same antigen-
presenting cells, FVIII was diluted in PBS and then mixed with an
equal volume of NPs before the treatment was administered to
the animals in these experiments.
Fig. 2. Therapeutic efficacy of SVP in FVIII primed mice. (A) Dose regimen. E16 mice were received 4 priming doses of 0.1 lg FVIII on days 0, 7, 14, and two doses of 1 lg FVIII
on days 34 and 42. Animals were administered two courses of 5 weekly treatments with either control empty NP or SVP concurrently with FVIII. (B) Day 51 pretreatment FVIII
inhibitor titers were determined by measuring Bethesda Units. (C) Anti-FVIII antibodies were determined by ELISA. (D) Anti-FVIII antibodies in animals treated with empty NP
(black) vs SVP (blue). (E) Day 75–159 FVIII inhibitor titers were determined by measuring Bethesda Units. (F) The correction of bleeding phenotype in the E16 mice as revealed
by% normalized hemoglobin (Hb) in a bleeding assay. *p < 0.05 and **p < 0.01 compared to empty NP group by Student t test with two tailed distribution. (For interpretation of
the references to color in this figure legend, the reader is referred to the web version of this article.)
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To test the ability of SVP containing only rapamycin to induce
tolerance prophylactically, groups of naïve E16 mice were injected
with immunogenic doses of FVIII admixed with either SVP or
empty NP, while a third group received FVIII plus a high dose of
intravenous immunoglobulin (IVIG), which is known to be
immunosuppressive (Fig. 3C).
After four weekly injections, all the mice in the control
group receiving empty NP + FVIII developed high titer anti-FVIII
Fig. 3. Prophylactic treatment for tolerance induction using SVP that contains rapamycin only. (A) Schematic illustration of SVPs encapsulating rapamycin alone. (B) FVIII
binds to SVP in vitro. Recombinant human FVIII (1 lg, diluted in 100 ll PBS) was added to 100 ll of F2 SVP and mixed by brief vortex. After incubation at room temperature
for 10 min, the mixture was separated by centrifugation at 16,000g for 10 min at 4 C. The pellet was reconstituted in 200 ll PBS. The FVIII activity of the supernatant (supe)
and of the reconstituted pellet (pellet) was immediately measured by chromogenic method. About 99% of the input FVIII activity was recovered. The result was expressed as
percentage of the input FVIII activity (mean ± SEM). (C) Dose regimen. Naïve E16 mice (n = 8) received weekly i.v. injection for 5 weeks with the mixture containing 100 ll of
FVIII (1 lg) in PBS plus 100 ll of either SVP, empty NP or IVIG (1 mg). After the final SVP treatment, the mice received multiple FVIII only challenge (1 lg) via i.v. or i.p. at day
57, 81, 125, 143, and 187, respectively. Blood samples were obtained one week after each FVIII exposure, and anti-FVIII antibody levels in the sera were determined by ELISA.
(D) Anti-FVIII antibodies in animals treated with SVP (blue), empty NP (black) or IVIG (Red). (E) and (F) Antigen specificity of the tolerance effect. The mice described were
immunized through i.v. with 2.5  108 pfu of uX174, a non-relevant antigen, at day 81, 95, and 143, respectively. At day 158, fifteen days after the last phage immunization,
blood samples were obtained, and the anti-uX174 antibody levels were determined by ELISA. In addition, the mice were also i.v. challenged with another non-relevant
antigen, sheep red blood cells (SRBC), at day 115 and 170, respectively. The anti-SRBC antibody titer in the serum one week after the second SRBC immunization was
determined by hemagglutination assay (HA). (E) Anti-PhiX174 antibody levels measured by ELISA. (F) The anti-SRBC HA titer. *p < 0.05 and **p < 0.01compared to empty NP
group by Student t test with two tailed distribution. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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antibodies. The SVP treatments effectively prevented anti-FVIII
antibody development throughout the course of the 5-week
treatment. The majority of anti-FVIII antibodies developed in mice
receiving empty NP + FVIII treatments was of IgG1 subtype.
Inhibitor titers were also determined which followed the same
trend as the antibody titers (Table 1). The group receiving IVIG plus
FVIII similarly developed low anti-FVIII antibody titers during the
treatment phase. However, upon cessation of treatment and fur-
ther challenge with FVIII, the IVIG-treated group developed titers
similar to those animals that received empty NP plus FVIII
(Fig. 3D).
In contrast, those mice that received SVP remained hyporespon-
sive to multiple challenges with FVIII. Remarkably, the FVIII toler-
ance state in the mice that received SVP plus FVIII treatments was
sustained for over 6 months despite multiple injections with
immunogenic doses of FVIII (Fig. 1D). These results indicate that
the IVIG induced only transient immunosuppression during the
period of treatment, while the SVPs induced durable immune
tolerance.
To rule out that SVP are inducing a chronic state of immunosup-
pression, we immunized the mice with two additional unrelated
antigens, bacteriophage uX174 and SRBC, both of which are
immunogenic without additional adjuvants, like FVIII. The two
groups produced similar levels of antibody responses to these
non-relevant antigens, indicating the efficacy of SVP + FVIII pro-
phylactic therapy was antigen-specific (Fig. 3E).
Although prevention of an immune response to FVIII was
achieved, reversal of antibody formation is more challenging and
relevant to FVIII inhibitor management. To test SVP in a therapeu-
tic protocol, E16 mice were injected weekly with recombinant
human FVIII to induce anti-FVIII antibody responses. The animals
were then distributed in a blinded manner so that the treatment
groups contained equal numbers of animals with similar titers.
Animals then received two courses of 5 weekly injections of SVP
containing rapamycin admixed with FVIII or empty NP plus FVIII
(Fig. 4A). During the first course of treatment, animals that
received SVP showed only a modest reduction in titers compared
to the control. However starting with the second course of treat-
ment, on Day 85, the SVP-treated mice showed a marked reduction
in anti-FVIII titers while the control animals showed a substantial
boost in titers. By day 113, mice treated with SVP plus FVIII were
significantly suppressed for anti-FVIII antibody production
(Fig. 4C). This effect also was specific as both groups responded
to TNP-SRBC (data not shown).
4. Discussion
4.1. SVP approach for FVIII immune tolerance
The immune response to therapeutic FVIII in hemophilia A is
the major factor rendering this therapy ineffective and potentially
life-threatening. Despite the wide use of ITI in treating inhibitor
formation, this approach is very expensive, involves long-term
treatment and is not always effective. To approach tolerance induc-
tion to FVIII, we employed nanoparticles that have been shown in
other models to induce antigen-specific immune tolerance [20].
The tolerogenic nanoparticle (SVP) are made with a polymer, PLGA,
that is biocompatible, biodegradable and used in multiple products
licensed for clinical use by regulatory agencies [28]. We have com-
bined it with an immunomodulatory agent, rapamycin, which has
been validated in humans and is capable of facilitating tolerance
[10,20,21,29,30]. The delivery of rapamycin by nanoparticles
allows for efficient transport to lymphoid organs and capture by
phagocytic antigen presenting cells (APCs) [20], and thus reduce
non-specific toxicity through chronic systemic administration. It
is of note that the weekly dose of rapamycin used in the SVP
approach was more than 6-fold less than in systemic delivery
reported by others [29,30]. For maximum efficacy, the dose and
frequency of SVP treatment will need to be further optimized in
future studies.
4.2. Different formulations of SVP
We previously reported that SVP encapsulating rapamycin as
well as a mixture of three MHC class II-binding FVIII peptides
induced specific tolerance to co-administered FVIII [20]. In this
study, we found that co-delivery of FVIII plus SVP containing
rapamycin only was equally effective, if not better, than SVP con-
taining both rapamycin and FVIII protein. This was attributed to
the fact that FVIII was able to bind to SVP when mixed together.
Since the SVP encapsulating FVIII peptides in previous report was
also administered together with FVIII, it could not be rule out that
part of the efficacy might be due to FVIII binding onto the SVP.
However, other protein antigens, e.g. OVA, did not bind to SVP in
significant amount (data not shown). Moreover, SVP containing
rapamycin could induce tolerance to other antigens, even when
the nanoparticles and the antigen were administered in separate
injections (RAM and TKK, unpublished data). The advantage of
using the SVP containing rapamycin alone is that it can be simply
added on to normal FVIII therapy in the clinic. However a potential
advantage of using the SVP that contains both FVIII and rapamycin
is that it could be used as a prophylactic vaccine to render patients
tolerant to FVIII prior to their first treatment. In the United States,
it is common for newly diagnosed hemophilia A patients to not
receive FVIII replacement therapy until there is a bleeding episode
that requires its use. Thus there is a window in which a newly
diagnosed infant could be tolerized to FVIII with SVP prior to the
first therapeutic use FVIII therapy. The advantage of encapsulating
the entire protein, rather than selected MHC class II-binding
peptides, is the dominant MHC class II peptides will vary from
individual to individual because of MHC class II heterogeneity,
whereas the FVIII protein contains all possible MHC class
II-binding epitopes.
4.3. Outlier response
The outcome of successful tolerance induction may depend on
the sum of many factors in each individual, including the ongoing
inflammation and/or infection. While the general trend of a poten-
tial tolerogenic efficacy is clear in this study, we did see several
outlier responses, e.g. in Fig. 1C and D. It is less likely that tolero-
genic SVP was directly responsible for the outlier response, consid-
ering the fact that SVP was not immunogenic, and up to four weeks
after the final prophylactic exposure to SVP there was still no mea-
sureable anti-FVIII antibody response developed. While determin-
ing the exact cause of lack of tolerance in individual animal is
important, it was out of the scope of our current study, and it
should not affect the main conclusion drawn.
Table 1
The effect of prophylactic treatment of SVP on antibody response to co-delivered
FVIII: two weeks after the final SVP treatment and before challenge.
Inhibitor titer Anti-FVIII antibodies (lg/ml)
(BU/ml) Total Abs IgG1 IgG2a
Empty NP 92.9 ± 2.5 23.34 ± 2.99 13.04 ± 2.87 1.78 ± 0.40
SVP 14.3 ± 7.2⁄⁄ 2.01 ± 1.11⁄⁄ 1.34 ± 0.80⁄⁄ 0.34 ± 0.05⁄⁄
IVIG 30.3 ± 5.6⁄⁄ 12.07 ± 5.22 1.33 ± 0.53⁄ 1.84 ± 1.01
*p < 0.05 and **p < 0.01; compared to empty NP group using Student-t test with two
tailed distribution.
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4.4. Mechanism of action
The precise mechanism of action by SVP remains to be deter-
mined. We know that antigen-presenting cells (APC) are attractive
targets for immunotherapies due to their central role in antigen
presentation to T cells and their ability for inducing tolerance.
Nanoparticles are ideal vehicles to deliver antigen and drugs to
APCs, as these cells are efficient in capturing particulate antigen,
such as viruses. Nanoparticulates injected are rapidly taken up by
antigen-presenting cells, such as macrophages and dendritic cells
[17–20]. The nanoparticle delivery of rapamycin and antigen to
the same APC may facilitate tolerogenic antigen presentation.
Indeed, SVP treatment inhibited expansion of antigen-specific T
cells and induced antigen-specific regulatory T cells (Treg) [20].
The total number of Tregs may not necessarily be increased. We
have looked at the frequency of total splenic Foxp3 + Tregs among
the CD4+ T cell populations by flow at the end of the experiment
described in Fig. 1 and did not find significant difference between
the two groups (data not shown). In future studies, among others,
functional activity of the induced specific Tregs by SVP treatment
will need to be assessed by adoptive transfer experiments.
4.5. Conclusion
We report in this study a new and effective method for immune
tolerance induction to therapeutic FVIII by utilizing PLGA nanopar-
ticles carrying immune modulating agent rapamycin as well as the
target antigen, FVIII protein. The addition of tolerogenic nanoparti-
cle strategy to FVIII replacement therapy has the potential to
improve the efficacy and safety profile of FVIII in the treatment
of hemophilia patients, either for prophylaxis or for purpose of
managing bleeding.
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